Regulation of Nausea and Vomiting by Cannabinoids and the Endocannabinoid System
Updated: Nov 8, 2018
Seizures are difficult to control in the Dravet syndrome, a rare genetic form of epileptic encephalopathy primarily due to loss-of-function mutations in the SCN1A gene. Interest in cannabidiol for the treatment of epilepsy was generated by media reports of efficacy in children with the Dravet syndrome. Four small trials of cannabidiol had yielded mixed results. A series of in vitro and in vivo preclinical models of seizure showed that cannabidiol had activity against convulsive seizures. Subsequently, the safety and effectiveness of a standardized oral solution of cannabidiol was tested in an open-label trial involving 214 children and young adults with drug-resistant epilepsy. We conducted a randomized, double-blind, placebo-controlled trial of cannabidiol to treat drug-resistant epilepsy in the Dravet syndrome.
SOURCE: New England Journal of Medicine
AUTHORS: Orrin Devinsky, M.D.,J. Helen Cross, Ph.D., F.R.C.P.C.H., Linda Laux, M.D., Eric Marsh, M.D., Ian Miller, M.D., Rima Nabbout, M.D., Ingrid E. Scheffer, M.B., B.S., Ph.D., Elizabeth A. Thiele, M.D., Ph.D., Stephen Wright, M.D.